Generic Aliqopa Availability
Last updated on Apr 10, 2025.
Aliqopa is a brand name of copanlisib, approved by the FDA in the following formulation(s):
ALIQOPA (copanlisib dihydrochloride - powder;intravenous)
-
Manufacturer: BAYER HEALTHCARE
Approval date: September 14, 2017
Strength(s): 60MG/VIAL (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aliqopa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Patent 10,383,876
Issued: August 20, 2019
Inventor(s): Peters Jan-Georg & Militzer Hans-Christian & Müller Hartwig
Assignee(s): BAYER INTELLECTUAL PROPERTY GMBHThe present invention relates:—to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;—to methods of preparing said dihydrochloride salt;—to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;—to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;—to a pharmaceutical composition comprising said dihydrochloride salt; and—to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agents.
Patent expiration dates:
- March 29, 2032✓✓
- March 29, 2032
-
Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Patent 9,636,344
Issued: May 2, 2017
Inventor(s): Peters Jan-Georg & Militzer Hans-Christian & Müller Hartwig
Assignee(s): Bayer Intellectual Property GmbHThe present invention relates
Patent expiration dates:
- March 29, 2032✓
- March 29, 2032
-
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Patent RE46856
Issued: May 22, 2018
Inventor(s): Hentemann Martin & Wood Jill & Scott William & Michels Martin & Campbell Ann-Marie & Bullion Ann-Marie & Rowley Bruce R. & Redman Aniko
Assignee(s): Bayer Intellectual Property GMBHThis invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
Patent expiration dates:
- October 22, 2029✓✓✓
- October 22, 2029
More about Aliqopa (copanlisib)
- Aliqopa consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: PI3K inhibitors
- Breastfeeding
- En español
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.